Related Experiment Video

Updated: May 5, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

19.0K

The Kinase Mirk/dyrk1B: A Possible Therapeutic Target in Pancreatic Cancer

Eileen Friedman1

  • 1Upstate Medical University, State University of New York, Syracuse, New York, NY 13210, USA. friedmae@upstate.edu.

Cancers
|November 28, 2013
PubMed

Insights

Pancreatic cancers contain many dormant cells resistant to standard treatments. The Mirk/dyrk1B kinase is elevated in these cells, promoting their survival and suggesting it as a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Pancreatic ductal adenocarcinomas exhibit resistance to chemotherapy and radiation.
  • A significant proportion (approx. 70%) of pancreatic cancer cells are out of cycle, including quiescent G0 cells resistant to cell division-targeting drugs.
  • These quiescent cells can repopulate tumors and contribute to treatment failure.

Purpose of the Study:

  • To identify novel therapeutic targets for pancreatic cancer, focusing on out-of-cycle cancer cells.
  • To investigate the role of the serine/threonine kinase Mirk/dyrk1B in pancreatic cancer cell survival and its potential as a selective therapeutic target.

Main Methods:

  • Analysis of nuclear Ki67 antigen in resected pancreatic tumors to assess cell cycle status.
  • Investigating the expression and function of Mirk/dyrk1B in quiescent pancreatic cancer cells.
  • Utilizing embryonic knockout studies in mice and RNA interference in cell cultures to assess Mirk's essentiality in normal cells.

Main Results:

  • Mirk/dyrk1B is identified as a downstream effector of oncogenic K-ras, a common mutation in pancreatic cancer.
  • Mirk expression is elevated in quiescent pancreatic cancer cells, mediating survival by upregulating antioxidant genes.
  • Mirk is expressed in approximately 90% of pancreatic cancers and amplified in a subset.
  • Mirk appears non-essential for normal cells but is upregulated in tumor cells.

Conclusions:

  • Mirk/dyrk1B plays a crucial role in the survival of quiescent pancreatic cancer cells.
  • The selective upregulation and non-essential nature of Mirk in normal cells suggest it as a promising, selective therapeutic target for pancreatic cancer.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.7K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.4K